Publications
297 results found
Petts G, Fisher RA, Short D, et al., 2014, Histopathological and Immunohistochemical Features of Early Hydatidiform Mole in Relation to Subsequent Development of Persistent Gestational Trophoblastic Disease, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 59, Pages: 213-220, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 8
Williams J, Short D, Dayal L, et al., 2014, Effect of Early Pregnancy Following Chemotherapy on Disease Relapse and Fetal Outcome in Women Treated for Gestational Trophoblastic Neoplasia, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 59, Pages: 248-254, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 17
Bonito NA, Drechsler J, Stoecker S, et al., 2014, Control of gp130 expression by the mitogen-activated protein kinase ERK2, ONCOGENE, Vol: 33, Pages: 2255-2263, ISSN: 0950-9232
- Author Web Link
- Cite
- Citations: 15
Pinato DJ, Shiner RJ, Seckl MJ, et al., 2014, Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer, BRITISH JOURNAL OF CANCER, Vol: 110, Pages: 1930-1935, ISSN: 0007-0920
- Author Web Link
- Open Access Link
- Cite
- Citations: 124
Sambasivan K, Mahmoud S, Kokache A, et al., 2014, Hypersensitivity reactions to etoposide phosphate, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, Vol: 20, Pages: 158-160, ISSN: 1078-1552
- Author Web Link
- Cite
- Citations: 11
Ngan HYS, Kohorn EI, Cole LA, et al., 2014, Trophoblastic disease (vol 119, pg S130, 2012), INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, Vol: 125, Pages: 93-93, ISSN: 0020-7292
Chuang S-C, Fanidi A, Ueland PM, et al., 2014, Circulating Biomarkers of Tryptophan and the Kynurenine Pathway and Lung Cancer Risk, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, Vol: 23, Pages: 461-468, ISSN: 1055-9965
- Author Web Link
- Cite
- Citations: 60
Agarwal R, Alifrangis C, Everard J, et al., 2014, Management and Survival of Patients with FIGO High-risk Gestational Trophoblastic Neoplasia, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 59, Pages: 7-12, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 25
Stavraka C, Pinato DJ, Turnbull SJ, et al., 2014, Developing an Objective Marker to Optimize Patient Selection and Predict Survival Benefit in Early-Phase Cancer Trials, CANCER, Vol: 120, Pages: 262-270, ISSN: 0008-543X
- Author Web Link
- Cite
- Citations: 13
Cuorvo LV, Verderio P, Ciniselli CM, et al., 2014, <i>PI3KCA</i> mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy, VIRCHOWS ARCHIV, Vol: 464, Pages: 85-93, ISSN: 0945-6317
- Author Web Link
- Cite
- Citations: 12
Agarwal R, Alifrangis C, Everard J, et al., 2014, Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010., J Reprod Med, Vol: 59, Pages: 7-12, ISSN: 0024-7758
OBJECTIVE: To present survival rates of high-risk gestational trophoblastic neoplasia (GTN) (FIGO score > 7) patients treated between 1995 and 2010 in the U.K. Death due to GTN is largely confined to patients with high-risk disease. In the U.K. a national system ensures that all patients are treated at only 2 specialist centers: Charing Cross Hospital (CXH) in London and Weston Park Hospital (WPH) in Sheffield. STUDY DESIGN: A total of 196 high-risk patients were identified using the CXH and WPH GTN databases, based on the risk score at the time of presentation. RESULTS: In all, 140 CXH and 56 WPH high-risk patients were treated with EMA/CO (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) and MEA (methotrexate, etoposide, actinomycin D), respectively. The FIGO score at presentation ranged from 6-23. Eight patients (7from WPH and 1 from CXH) who were treated prior to 2002 as high-risk based on their pre-2002 scoring scored a 6 using FIGO 2002. Two (1%) patients died within 4 weeks of starting treatment (early death), 12 (6%) relapsed, and 9 patients subsequently died due to drug resistance. The overall survival was 94%, with a median follow-up of 4.69 years. CONCLUSION: In the context of a national trophoblastic disease service, patients with high-risk GTN have an excellent prognosis with EMA/CO or MEA.
Seckl MJ, Roy R, Mauri F, et al., 2013, FGF-2 INDUCES CHEMORESISTANCE IN MODEL AND LUNG CANCER CELLS THROUGH S6K2/HNRNPA1-MEDIATED ENHANCED TRANSLATION OF ANTI-APOPTOTIC PROTEINS, JOURNAL OF THORACIC ONCOLOGY, Vol: 8, Pages: S1037-S1038, ISSN: 1556-0864
Seckl MJ, Ottensmeier C, Cullen M, et al., 2013, A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC), JOURNAL OF THORACIC ONCOLOGY, Vol: 8, Pages: S219-S219, ISSN: 1556-0864
Kaliszczak M, Pardo OE, Seckl MJ, et al., 2013, HDAC6 inhibitor C1A abrogates the recruitment of the autophagic machinery and synergizes with proteasome, src kinase, and PI3K-mTOR inhibition., MOLECULAR CANCER THERAPEUTICS, Vol: 12, ISSN: 1535-7163
Tang H, Li H, Wang Y, et al., 2013, Combined preparation and application of combined preparation in preparing non-small-cell lung carcinoma drug, CN103330940A
The invention discloses a combined preparation and an application of the combined preparation in preparing a non-small-cell lung carcinoma drug. An EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and a preparation for increasing a concentration of glutathione (GSH) in lung carcinoma cells are administered simultaneously or successively. According to the combined preparation and the application, through a systemic research, the GSH plays an important role in resisting the EGFR tyrosine kinase inhibitor to an EGFR T790M mutation non-small-cell lung carcinoma, so that drug resisting cells are sensitive to treatment of the EGFR tyrosine kinase inhibitor again by utilizing a mode of increasing the concentration of the GSH in the lung carcinoma cells; and a cell experiment and an animal experiment prove that the method is safe and effective, can effectively kill the lung carcinoma cells, and can inhibit proliferation of the lung carcinoma cells.
Seckl MJ, Sebire NJ, Fisher RA, et al., 2013, Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, Vol: 24, Pages: 39-50, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 231
Niemann I, Fisher R, Short D, et al., 2013, RISK OF PERSISTENT TROPHOBLASTIC DISEASE AND CHANCE OF HEALTHY BABY IN TWIN PREGNANCIES WITH COMPLETE HYDATIDIFORM MOLE AND NORMAL CO-TWIN, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 23, ISSN: 1048-891X
Bolze P-A, Weber B, Fisher RA, et al., 2013, First confirmation by genotyping of transplacental choriocarcinoma transmission, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, Vol: 209, Pages: E4-E6, ISSN: 0002-9378
- Author Web Link
- Cite
- Citations: 7
Lara R, Seckl MJ, Pardo OE, 2013, The p90 RSK Family Members: Common Functions and Isoform Specificity, CANCER RESEARCH, Vol: 73, Pages: 5301-5308, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 90
Pardo OE, Seckl MJ, 2013, S6K2: The Neglected S6 Kinase Family Member., Frontiers in Oncology, Vol: 3, ISSN: 2234-943X
S6 kinase 2 (S6K2) is a member of the AGC kinases super-family. Its closest homolog, S6K1, has been extensively studied along the years. However, due to the belief in the community that the high degree of identity between these two isoforms would translate in essentially identical biological functions, S6K2 has been largely neglected. Nevertheless, recent research has clearly highlighted that these two proteins significantly differ in their roles in vitro as well as in vivo. These findings are significant to our understanding of S6 kinase signaling and the development of therapeutic strategies for several diseases including cancer. Here, we will focus on S6K2 and review the protein-protein interactions and specific substrates that determine the selective functions of this kinase.
Sita-Lumsden A, Medani H, Fisher R, et al., 2013, Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6, BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 120, Pages: 1012-1015, ISSN: 1470-0328
- Author Web Link
- Cite
- Citations: 25
Savage P, Sebire N, Dalton T, et al., 2013, Partial molar pregnancy after intracytoplasmic sperm injection occurring as a result of diploid sperm usage, JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, Vol: 30, Pages: 761-764, ISSN: 1058-0468
- Author Web Link
- Cite
- Citations: 10
You B, Harvey R, Henin E, et al., 2013, Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements, BRITISH JOURNAL OF CANCER, Vol: 108, Pages: 1810-1816, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 34
Savage PM, Sita-Lumsden A, Dickson S, et al., 2013, The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome, JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 33, Pages: 406-411, ISSN: 0144-3615
- Author Web Link
- Cite
- Citations: 61
Miller RE, Dudderidge T, Huddart R, et al., 2013, Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours, BJU INTERNATIONAL, Vol: 111, Pages: E152-E157, ISSN: 1464-4096
- Author Web Link
- Cite
- Citations: 12
Saso S, Naji O, Ismail L, et al., 2013, First Case of Pregnancy following a Modified Strassman Procedure, Society of Gynecologic Oncology
Fallahian M, Sebire NJ, Savage PM, et al., 2013, Mutations in NLRP7 and KHDC3L Confer a Complete Hydatidiform Mole Phenotype on Digynic Triploid Conceptions, HUMAN MUTATION, Vol: 34, Pages: 301-308, ISSN: 1059-7794
- Author Web Link
- Cite
- Citations: 41
Alifrangis C, Agarwal R, Short D, et al., 2013, EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis, JOURNAL OF CLINICAL ONCOLOGY, Vol: 31, Pages: 280-286, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 135
Wojtalla A, Fischer B, Kotelevets N, et al., 2013, Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer, CLINICAL CANCER RESEARCH, Vol: 19, Pages: 96-105, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 26
Sebire NJ, Savage PM, Seckl MJ, et al., 2013, Histopathological features of biparental complete hydatidiform moles in women with <i>NLRP7</i> mutations, PLACENTA, Vol: 34, Pages: 50-56, ISSN: 0143-4004
- Author Web Link
- Cite
- Citations: 32
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.